Korean Celltrion Gears Up To Produce Biosimilar Herceptin, Remicade, Erbitux; Proposes Barter System In Developing Regions

SEOUL - "Celltrion is currently developing a total of nine blockbuster antibody therapeutic biosimilars, and we are preparing for the launch of three biosimilars for markets not protected with patent rights," Kim Yong-Joong, Celltrion's strategic planning assistant manager, told PharmAsia News